ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Brazilian court strips Gilead of its patent for Hepatitis C drug Sovaldi
September 30, 2018A judge from the 21st Federalist Court of Brasilia has ruled to invalidate US biopharma company Gilead’s exclusivity patent for Sovaldi (sofosbuvir), which is indicated for Hepatitis C. -
Gilead to launch authorised generic versions of hepatitis C drugs Epclusa, Harvoni next year in US
September 25, 2018Gilead Sciences announced Monday that it plans to launch authorised generic versions of its hepatitis C therapies Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the US next year. -
Gilead lowers the price to launche hep C drug Sovaldi in China
November 30, 2017Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it will cost 58,980 yuan in the region, just one-fifth of its price tag in the US – a price which has fallen rapidly from the $84,0 -
FDA approves new indications for Harvoni and Sovaldi
April 11, 2017First HCV direct-acting antivirals approved for use in adolescents.
Pharma Sources Insight January 2025
